Chantai Biological

Chantai Biological is a clinical-stage biotechnology company based in Changzhou, China, specializing in the development of innovative cell therapies for solid tumors. The company focuses on Chimeric Antigen Receptor T-cell (CAR-T) and T-cell Receptor (TCR-T) technologies, aiming to address the unmet medical needs of patients with advanced cancers. Its lead candidate, CT-01, is a GPC3-targeted CAR-T therapy currently being evaluated in Phase 1/2 clinical trials for the treatment of hepatocellular carcinoma. Chantai Biological utilizes its proprietary technology platforms to enhance the persistence and efficacy of T-cells within the immunosuppressive tumor microenvironment. The company is supported by prominent venture capital firms and maintains state-of-the-art R&D and manufacturing facilities in China.